[Insulin therapy using a new injection device. Experience with 36 type I diabetics]

Area of Science:

• Endocrinology
• Metabolic Disorders
• Diabetes Management

Context:

• Type 1 diabetes management often involves conventional insulin therapy.
• Achieving optimal glycemic control remains a challenge for many patients.
• New insulin delivery devices and treatment regimens are continuously explored.

Purpose:

• To evaluate the efficacy of the basic bolus insulin principle using NovoPen in type 1 diabetics.
• To assess changes in metabolic status and daily insulin requirements.
• To determine patient satisfaction with the new injection device and treatment approach.

Summary:

• Thirty-six type 1 diabetes patients transitioned from conventional therapy to a basic bolus regimen (ultralong-acting insulin plus preprandial rapid-acting insulin) via NovoPen.
• Over four months, significant improvement in HbA1c levels (9.4% to 8.41%) was observed (P<0.01) with similar daily insulin doses (42.7 IU to 43.5 IU).
• Patients reported positive experiences with the NovoPen's handling and technique.

Impact:

• The basic bolus principle, combined with devices like NovoPen, can enhance glycemic control in type 1 diabetes.
• This approach is particularly beneficial for patients with suboptimal blood sugar control or existing diabetic complications.
• Improved metabolic compensation may aid in preventing or managing secondary diabetic lesions, leading to a greater quality of life.